FDA Accelerated Approval: what it means for patients outside the US
A plain explanation for patients, families and doctors, checked against the regulator's own pages on 17 October 2026.
Reviewed by the Reserve Meds clinical operations team on 17 October 2026. Sources accessed 17 October 2026.
The short answer
FDA Accelerated Approval lets a medicine for a serious condition with an unmet need be approved earlier, based on a surrogate endpoint that is reasonably likely to predict clinical benefit. The company must still run confirmatory trials. If they fail to show benefit, FDA can remove the approval. An accelerated-approval medicine is fully FDA-approved and can be requested from abroad like any other.
- Who runs it: US Food and Drug Administration (FDA).
- Since: 1992 regulations, expanded by FDASIA in 2012.
- Key condition: Confirmatory trials after approval.
- Price: Quote on request for any medicine.
What accelerated approval is
FDA set up accelerated approval to allow earlier approval of drugs that treat serious conditions and fill an unmet medical need, based on a surrogate endpoint. A surrogate endpoint is a marker, such as a laboratory measurement, radiographic image or physical sign, that is thought to predict clinical benefit but is not itself a measure of benefit. Using one can shorten the time to approval considerably.[1]
FDA introduced the accelerated approval regulations in 1992. In 2012, section 901 of the Food and Drug Administration Safety and Innovation Act (FDASIA) amended the law so accelerated approval can also rest on an intermediate clinical endpoint, a measure reasonably likely to predict benefit, such as an effect on irreversible morbidity or mortality.[2]
Confirmatory trials and what happens if they fail
Companies are still required to run studies to confirm the expected clinical benefit. If the confirmatory trial shows benefit, FDA grants traditional approval. If it does not, FDA has procedures that can lead to removing the drug from the market. FDA publishes lists of ongoing, verified and withdrawn accelerated approvals, updated quarterly.[1]
For a family, this means the US label tells you the status. Labels for accelerated-approval indications state that the indication is approved under accelerated approval and that continued approval may depend on a confirmatory trial.
Examples from medicines we cover
Several medicines in our catalog carry accelerated-approval wording in their current US labels. For example, the label for Qalsody (tofersen) for SOD1 ALS states the indication was approved under accelerated approval based on reduction in plasma neurofilament light chain. The labels for Modeyso for H3 K27M diffuse midline glioma, Ojemda for pediatric low-grade glioma and Voxzogo for achondroplasia also state accelerated approval.[3, 4, 5, 6]
How an accelerated-approval medicine reaches a patient in the Gulf
Why this matters in the Gulf: Saudi Arabia's SFDA runs reliance pathways that build on decisions by other regulators. Its performance target is 30 working days for the verification pathway, which needs approval and marketing by both the US FDA and the EMA, and 60 working days for the abridged pathway, which needs one of them. The manufacturer still has to apply; nothing happens automatically.[7]
Until a medicine is registered locally, a patient in the Gulf usually reaches an FDA-approved medicine through a hospital request to the national regulator, such as the SFDA Special Access Program in Saudi Arabia or the procedure in NHRA Circular 41 of 2020 in Bahrain.[8, 9]
The treating specialist should read the US label with the family, including the accelerated-approval statement, so everyone understands what the evidence shows today and what is still being confirmed.
How FDA's four expedited programs compare
- Fast Track: for drugs that treat serious conditions and fill an unmet need. It brings more frequent FDA meetings and written communication, possible rolling review of completed sections of the application, and eligibility for accelerated approval and priority review if criteria are met.[10]
- Breakthrough Therapy: for drugs whose early clinical evidence suggests substantial improvement over available therapy. It includes all Fast Track features plus intensive guidance from Phase 1 and senior management involvement.[11]
- Accelerated Approval: an approval based on a surrogate or intermediate endpoint reasonably likely to predict benefit, with confirmatory trials required.[1]
- Priority Review: FDA's goal is to act on the application within 6 months, compared with 10 months under standard review. We give you a written timeline estimate for your case before you commit.[12]
Only accelerated approval is an approval. The other three change how a drug is developed or reviewed; none of them makes a drug available before approval.
How Reserve Meds helps
Reserve Meds is a digital health company. Medicines are supplied through a US-licensed pharmaceutical wholesale partner. We help families and treating doctors understand the route, prepare the documents the regulator or hospital asks for, arrange supply from the US once approval is in place, and keep everyone updated. We do not diagnose, prescribe or decide what a regulator approves.
We coordinate access to FDA-approved medicines only. Investigational medicines are only available through a manufacturer's expanded-access program requested by the treating physician; we can explain that route, but we do not supply them. Your coordination fee is quoted in writing for your case before you commit. No hidden charges. We give you a written timeline estimate for your case before you commit.
Ask us whether a medicine can reach your patient
Tell us the medicine, your country and a WhatsApp or phone number. We reply within one business day. On WhatsApp we usually reply the same day.
Frequently asked questions
Is an accelerated-approval medicine fully approved by FDA?
Yes. It is an FDA approval, but continued approval may depend on confirmatory trials. If those do not show clinical benefit, FDA can take steps that may lead to removal.
What is a surrogate endpoint?
A marker, such as a lab test, scan result or physical sign, that is thought to predict clinical benefit but is not itself a measure of benefit.
Can a patient in Saudi Arabia get a medicine approved under accelerated approval?
Yes, through the same routes as any FDA-approved medicine: local supply if it is registered, or a hospital request to the SFDA Special Access Program if it is not.
Does accelerated approval mean the medicine is less safe?
Not by itself. It means the benefit was shown on a surrogate or intermediate endpoint and is still being confirmed. The label lists the known risks, and the treating specialist weighs them for the patient.
Sources for these answers: [1, 2, 8]
Sources
All sources were opened and checked on 17 October 2026. Rules and labels change, so the treating hospital or regulator confirms the current position before anything is filed.
- US FDA: Accelerated Approval Program (accessed 17 October 2026)
- US FDA: Accelerated Approval (information for patients) (accessed 17 October 2026)
- DailyMed: Qalsody (tofersen) US prescribing information, version effective 13 November 2024 (accessed 17 October 2026)
- DailyMed: Modeyso (dordaviprone) US prescribing information, version effective 9 January 2026 (accessed 17 October 2026)
- DailyMed: Ojemda (tovorafenib) US prescribing information, version effective 2 September 2025 (accessed 17 October 2026)
- DailyMed: Voxzogo (vosoritide) US prescribing information, version effective 25 November 2025 (accessed 17 October 2026)
- SFDA: Verification and Abridged Pathways guidance, version 3.0 (October 2025) (accessed 17 October 2026)
- SFDA: Special Access Program (SAP) guidance, version 1.0 (accessed 17 October 2026)
- NHRA Bahrain: Circular No. (41) of 2020, procedures for importing non-registered medicines (accessed 17 October 2026)
- US FDA: Fast Track (information for patients) (accessed 17 October 2026)
- US FDA: Breakthrough Therapy (accessed 17 October 2026)
- US FDA: Priority Review (information for patients) (accessed 17 October 2026)
Related
- Breakthrough Therapy designation
- Priority review vouchers
- All access pathways
- US expanded access (compassionate use)
- Named-patient access, explained
- Answers to common access questions
This page is general information, not medical or legal advice. It does not replace advice from your own doctor or the regulator.